Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Harry Sweigard
SM16, an Orally Active TGF- Type I Receptor Inhibitor Prevents Myofibroblast Induction and Vascular Fibrosis in the Rat Carotid Injury Model
Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular Medicine
Cardiology
Related publications
An Orally Active Chemokine Receptor CCR2 Antagonist Prevents Glomerulosclerosis and Renal Failure in Type 2 Diabetes
Kidney International
Nephrology
A Novel Small-Molecule Inhibitor of Transforming Growth Factor Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth in Vivo and Prevents Tumor Recurrence After Surgical Resection
Cancer Research
Cancer Research
Oncology
MEK Inhibition Prevents TGF‑β1‑induced Myofibroblast Transdifferentiation in Human Tenon Fibroblasts
Molecular Medicine Reports
Oncology
Genetics
Molecular Biology
Biochemistry
Cancer Research
Molecular Medicine
Toll-Like Receptor 7-Mediated Type I Interferon Signaling Prevents Cholestasis- And Hepatotoxin-Induced Liver Fibrosis
Hepatology
Medicine
Hepatology
Orally Active Epoxyeicosatrienoic Acid Analog Attenuates Kidney Injury in Hypertensive Dahl Salt-Sensitive Rat
Hypertension
Internal Medicine
In the Absence of Type III Receptor, the Transforming Growth Factor (TGF)-β Type II-B Receptor Requires the Type I Receptor to Bind TGF-β2
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
Development of an ALK2-Biased BMP Type I Receptor Kinase Inhibitor
ACS Chemical Biology
Biochemistry
Medicine
Molecular Medicine
LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis and Vasculopathy in a Rat Model of Chronic Kidney Disease
Journal of Cardiac Failure
Cardiovascular Medicine
Cardiology
TACE-Mediated Ectodomain Shedding of the Type I TGF-β Receptor Downregulates TGF-β Signaling
Molecular Cell
Cell Biology
Molecular Biology
